GALECTIN THERAPEUTICS INC (NASDAQ:GALT) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 13, 2026.
At publication ·
GALECTIN THERAPEUTICS INC (NASDAQ:GALT) · proxy filed
At a glance
GALECTIN THERAPEUTICS INC (NASDAQ:GALT) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 13, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
GALECTIN THERAPEUTICS INC's stock currently trades at $3.69 with a market capitalization of $369.9M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing GALECTIN THERAPEUTICS INC's filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for GALECTIN THERAPEUTICS INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View GALT Stock Page
Browse all filings on our GALT SEC filings page.
Public companies like GALECTIN THERAPEUTICS INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · GALT
$3.47
Down: -$0.49 · -13.98%
Live quote updated
Keep reading
